Astonea Labs Reports Nil Deviation in IPO Proceeds Utilisation for Sep'26 Half-Year
Astonea Labs Ltd 路 Others (Uncategorized) 路 15 Nov 2026, 2:16 am
Astonea Labs Reports Nil Deviation in IPO Proceeds Utilisation for Sep'26 Half-Year Astonea Labs Limited reported nil deviation or variation in the utilisation of its IPO proceeds for the half year ended 30th Sep'26 under Regulation 32 of SEBI LODR. Out of total funds raised amounting to Rs 37.67 cr through the issuance of 27.90 lakh equity shares, the company utilised Rs 36.43 cr across key objectives, including working capital (Rs 19.75 cr) and equity investment in Damaira Pharmaceuticals (Rs 6.25 cr). The unutilised balance stands at Rs 1.23 cr as of 30th Sep'26.
Original exchange filing (PDF)
More announcements from Astonea Labs Ltd
- Revised Outcome of Board Meeting held on 14th November, 2026 路 15 Nov 2026
- Unaudited Financial Results (Standalone & Consolidated) for the half year ended 30th September, 2026 路 14 Nov 2026
- Outcome of Board Meeting held on 14th November, 2026 路 14 Nov 2026
- Astonea Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve unaudited Standalone and Consolidated .... 路 14 Nov 2026
- Please find enclosed herewith an Intimation regarding change in the Corporate Identification Number (CIN) of the Company consequent upon alteration of the Object Clause of the Memorandum .... 路 09 Oct 2026
- Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 - Incorporation of Proposed Subsidiary- Longevity Science Private Limited 路 08 Oct 2026
- Please find enclosed herewith re-submission of financial results for the half year and year ended 31.03.2025. 路 22 Sept 2026
- Please find enclosed herewith resubmission of financial results for the financial year ended 31.03.2025, as the same was submitted in XBRL Version and as a part of outcome of the Board .... 路 19 Sept 2026
